newsfilter
← Latest News
GlobeNewswire·

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Phase 1b trial in Alzheimer's disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolledPMN310 continues to demonstrate a favorable safety profileOn track to report 6-month interim data in Q2 2026 and final